Donald Trump’s proposed 200% tariff on generic drug imports is less a blow to India’s pharmaceutical industry than a costly gamble that could leave American patients paying the highest price.
In an election that is shaping up to be a fierce contest, 1% or 2% of the vote in the most critical battleground states can make all the difference between winning and losing[.]